The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Arbutus Biopharma Corporation (ABUS) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.0082, or 0.39%, to $2.1082. The Arbutus Biopharma Corporation has recorded 24,308 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Arbutus to Participate in Two Upcoming Investor Conferences.
Arbutus Biopharma Corporation is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Arbutus Biopharma Corporation is $348.49M. A total of 0.66 million shares were traded on the day, compared to an average of 620.81K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, ABUS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 10 BUYs and 0 SELLs from insiders. Insiders purchased 1,062,200 shares during that period but sold 0.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for ABUS in the last 3 months, the mean price target is $5.40 with high estimates of $6.00 and low estimates of $4.00. In terms of 52-week highs and lows, ABUS has a high of $3.14 and a low of $1.85.
As of this writing, ABUS has an earnings estimate of -$0.11 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.1 per share and a lower estimate of -$0.13. The company reported an EPS of -$0.1 in the last quarter, which was 28.60% higher than expectations of -$0.14.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ABUS’s latest balance sheet shows that the firm has $155.32M in Cash & Short Term Investments as of fiscal 2021. There were $2.61M in debt and $11.22M in liabilities at the time. Its Book Value Per Share was $0.81, while its Total Shareholder’s Equity was $169.44M.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ABUS is Buy with a score of 5.00.